Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Halozyme to buy Elektrofi for $750 million to expand drug delivery lineup
07:16am, Wednesday, 01'st Oct 2025
Halozyme Therapeutics said on Wednesday it will buy privately held Elektrofi for $750 million in cash, to expand its lineup with a technology that can deliver biologic medicines in small, concentrated
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
07:00am, Wednesday, 01'st Oct 2025
Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are approved blockbusters today Highly scalable licensing model and long duration IP
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:42am, Thursday, 25'th Sep 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Nexalin Technology Announces Issuance of U.S. Patent Covering HALO™ Clarity Device Featuring DIFS™ Technology
08:30am, Thursday, 25'th Sep 2025
HOUSTON, TX, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader in Deep Intracranial Frequency Stimulation (DIFS™) of t
Powell Warns of Valuation Risks: 5 High Earnings Yield Value Picks
10:26am, Wednesday, 24'th Sep 2025
Powell flags lofty valuations, but five high-earnings-yield stocks stand out as value picks in a cautious market.
5 Biotech Stocks Worth Adding to Your Portfolio Now
10:25am, Tuesday, 23'rd Sep 2025
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the Unit
Bull of the Day: Halozyme Therapeutics (HALO)
06:20am, Tuesday, 23'rd Sep 2025
Halozyme Therapeutics ( HALO ) is a $9 billion biotech focused on oncology and boasting sales and profit growth of 29% and 46%, respectively, while trading a sub-11x forward P/E. HALO is focused on th
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know
01:02pm, Friday, 19'th Sep 2025
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
10:02am, Friday, 19'th Sep 2025
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
5 High Earnings Yield Stocks to Buy Ahead of Potential Fed Rate Cuts
10:55am, Tuesday, 09'th Sep 2025
As Fed rate cuts loom, value investors may eye HALO, PARR, BPOP, PHIN and KT - stocks with high earnings yield and growth potential.
Halozyme Therapeutics, Inc. (HALO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
10:29am, Monday, 08'th Sep 2025
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:45 AM EDT Company Participants Helen Torley - President, CEO & Director Conferenc
Bet on These 3 Stocks With Upgraded Broker Ratings for Robust Returns
10:10am, Friday, 05'th Sep 2025
Broker upgrades boost Halozyme, Leidos and TransUnion, each projected for solid 2025 earnings growth and stronger returns.
Halozyme Therapeutics, Inc. (HALO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Prepared Remarks Transcript
05:34pm, Thursday, 04'th Sep 2025
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 1:30 PM EDT Company Participants Helen Torley - President, CEO & Director Conference Cal
4 PEG-Rated GARP Stocks That Offer Both Value and Growth
11:55am, Thursday, 04'th Sep 2025
Halozyme, Phibro, Leidos and PDD Holdings stand out as PEG-rated GARP picks, blending value and growth with solid long-term potential.
Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics (HALO) is a Great Choice
01:01pm, Wednesday, 03'rd Sep 2025
Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.
